Clausen, K., et al., “Studies on amino acids and peptides. II. Synthesis of protected endothiodipeptides,” J. Chem. Scr., 1982, 20(1-2), 14-18, doc. No. 97:163474 (abstract only, 1 page). |
Frank, R., et al., “Extremely mild reagent for Boc deprotection,” J. Chem. Commun. (Cambridge), 1996, 22, 2509-2510, doc. No. 126:104395 (abstract only, 3 pages). |
Kobayashi, A., et al., “Syntheses of 2-dialkylamino-4,4-disubstituted 5 (4H)-thiazolones,” J. Yakugaku Zasshi, 1970, 90(11), 1377-1380, doc. No. 74:31713 (abstract only, 3 pages). |
Koenig, H.B., et al., “.beta-Lactam antibiotics,” Ger. Offen., 41 pages, doc. No. 83:97276 (abstract only, 5 pages), 1975. |
Masuda, T., Jpn. Kodai Tokkyo Koho, 22 pages, doc. No. 115:280022 (abstract only, 1page), 1991. |
Pfeifer, T., et al., “Specific fragmentation of thioxo peptides facilitates the assignment of the thioxylated amino acid,” J. Mass Spectrom, 1997, 32(10), 1064-1071, doc. No. 127:331738 (abstract only 2 pages). |
Sawa, N., et al., “Preparation of 4(5)-thiocarbamoylimoylimidazole compounds,” Jpn. Kokai Tokkyo Koho, 33 pages, doc. No. 115:183296 (abstract only, 2 pages), 1991. |
Schutkowski, M., et al., “Inhibition of peptidyl-prolyl cis/trans isomerase activity by substrate analog structures: thioxo tetrapeptide-4-nitroanilides,” Biochemistry, 1995, 34(40), 13016-13026, doc. No. 123:221511 (abstract only, 4 pages). |
“Cephalosporins,” Jpn. Kokai Tokkyo Koho, 40 pages, doc. No. 99:5433 (abstract only, 2 pages), 1982. |
Buckle, D.R., et al., “Non Thiazolidinedione Antihyperglycaemic Agents. 1: α-Heteroatom Substituted β-Phenylpropanoic Acids,” Bioorg. Med. Chem. Lett., 1996, 6(17), 2121-2126. |
Keenan, R.M. et al., “Discovery of Potent Nonpeptide Vitronectin Receptor (avβ3) Antagonists,” J. Med. Chem., 1997, 40(15), 2289-2292. |
McDowell, R.S. et al., “From Peptide to Non-Peptide. 2. The de Novo Design of Potent, Non-Peptidal Inhibitors of Platelet Aggregation Based on a Benzodiazepinedione Scaffold,” J. Am. Chem. Soc., 1994, 116, 5077-5083. |
Miller, W.H. et al., “Structure-Activity Relationships in 3-Oxo-1,4-Benzodiazepine-2-Acetic Acid GPIIb/IIIa Antagonists. The 2-Benzazepine Series,” Bioorg. Med. Chem. Lett., 1996, 6(21), 2481-2486. |
Ukai, Y. et al., “A novel synthetic inhibitor of endopeptidase-24;15,” Chemical Abstracts, 1997, 127(2), 1 page. |
Venturella, V.S. et al., “Substituted 1,3-Dihydro-4H-furo[3,4-d]-1,3-benzodiazepin-3-ones: Synthesis and Scope of the Method,” J. Heterocyclic Chem., 1969, 6(5), 671-679. |
Wojciechowska, H. et al., “Preparation of 2,4-dinitrophenyl derivatives of tyrosine,” Chemical Abstracts, 1968, 68(25), Abstract No. 114926r, 1 page. |
Lobb, R.R., et al., “Small molecule antagonists of alpha4 integrins: novel drugs for asthma,” Exp. Opin, Invest. Drugs, 1999, XP000885957, 8(7), 935-945. |
Samanen, J., et al., “Vascular indications for integrin alpha V antagonists,” Current Pharm. Design., 1997, 3, 545-584. |
{haeck over (S)}avrda, J., “CIS-TRANS isomerism of N-ACYL derivatives of proline and its analogues, linear peptides with CIS peptide bonds,”Proc. 14th European Peptide Symposium, Loffet, A. (ed.), 1976, 653-656. |
Azzouny, A.E., et al., “Synthesis of some N-substituted salicylamides structurally related to certain antimicrobials,” Pharmazie, 1977, 32(6), 318-323 (abstract). |
Badshah, A., et al., “Catalytic reduction of azlactones in alkaline media. Synthesis of amino acids,” J. of Organic Chemistry, 1972, 37(18), 2916-2918. |
Tous, G., et al., “O'-(Epoxyalkyl) tyrosines and (Epoxyalkyl) phenylalanine as irreversible inactivators of serine proteases: synthesis and inhibition mechanism,” J. of Medicinal Chemistry, 1990, 33(6), 1620-1634. |